Nucleome Therapeutics Email Format

Biotechnology ResearchEngland, United Kingdom51-200 Employees

Nucleome Therapeutics is a biotechnology company based in Oxford, England, that uses 3D genomics to inform drug discovery. Its approach aims to raise the odds of success by identifying genetically validated targets and by better identifying patients who are likely to benefit from treatments. The platform is applicable across multiple disease indications and cell types, with an initial focus on inflammatory conditions, and it supports both its own pipeline development and external collaborations in target discovery, target validation, and patient stratification. The company was founded in 2019 by gene regulation experts from the University of Oxford. In the biotechnology research sector, Nucleome positions itself at the intersection of spatial genomics and translational medicine, pursuing collaborations with external partners to advance target discovery, validation, and patient stratification. A recent development is the appointment of Dr. Michelle Morrow as Chief Scientific Officer in February 2026, reflecting ongoing leadership expansion.

Get verified Nucleome Therapeutics emails free

Company overview Employee directory